$DRIO DarioHealth Appoints Digital Therapeutics Pioneer Dr. Abigail Hirsch to Its Advisory Board to Support Commercial Strategy and Execution
CAESAREA, Israel and NEW YORK, Oct. 22, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"
, a leading, global digital therapeutics company, has appointed Dr. Abigail Hirsch to its Advisory Board where she will help guide commercial and Business-to-Business (B2B) efforts.
Dr. Hirsch has many years of experience utilizing clinical psychology, data analytics and educational design to create innovative healthcare technology that helps people lead healthier, more fulfilling lives.
Prior to joining Dario, Dr. Hirsch served as Chief Clinical Officer at a behavioral health company called myStrength, helping lead the company from inception through its acquisition by Livongo Health, Inc. in the first quarter of 2019. She holds a Ph.D. in Clinical Psychology from the University of Massachusetts.
"Dr. Hirsch has an impressive track record of successfully advancing the development of digital therapeutic programs in the health tech industry. She brings her extensive experience to DarioHealth's digital chronic condition management platform. This is particularly relevant because of the behavioral components in our platform which integrate data collection and analytics with coaching and digital lifestyle management. We expect Dario will benefit greatly from her unique perspective and guidance as she helps shape our position in the field of chronic condition management," said Erez Raphael, CEO.
Dr. Hirsch added, "I love Dario's solution and am very excited to be joining their team. Dario's unique digital therapeutics platform is distinguished by its client-centered approach. This facet of the technology has proven successful in engaging users to better manage their health. I look forward to working closely with the Dario team as we further penetrate the B2B market with solutions that advance the management of chronic conditions while positively impacting patients, providers and payers."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://mydario.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company" related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes its expectation that it will benefit greatly from Dr. Hirsch's unique perspective and guidance as she helps shape its position in the field of chronic condition management and that Dr. Hirsch will work closely with the Dario team as it further penetrates the B2B market with solutions that advance the management of chronic conditions while positively impacting patients, providers and payers, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1 347-767-4220
https://c212.net/c/img/favicon.png?sn=LN11562...2019-10-22 View original content to download multimedia:http://www.prnewswire.com/news-releases/dariohealth-appoints-digital-therapeutics-pioneer-dr-abigail-hirsch-to-its-advisory-board-to-support-commercial-strategy-and-execution-300942898.html
SOURCE DarioHealth Corp.
CAESAREA, Israel and NEW YORK, Oct. 22, 2019 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("DarioHealth" or "Dario"
, a leading, global digital therapeutics company, has appointed Dr. Abigail Hirsch to its Advisory Board where she will help guide commercial and Business-to-Business (B2B) efforts. Dr. Hirsch has many years of experience utilizing clinical psychology, data analytics and educational design to create innovative healthcare technology that helps people lead healthier, more fulfilling lives.
Prior to joining Dario, Dr. Hirsch served as Chief Clinical Officer at a behavioral health company called myStrength, helping lead the company from inception through its acquisition by Livongo Health, Inc. in the first quarter of 2019. She holds a Ph.D. in Clinical Psychology from the University of Massachusetts.
"Dr. Hirsch has an impressive track record of successfully advancing the development of digital therapeutic programs in the health tech industry. She brings her extensive experience to DarioHealth's digital chronic condition management platform. This is particularly relevant because of the behavioral components in our platform which integrate data collection and analytics with coaching and digital lifestyle management. We expect Dario will benefit greatly from her unique perspective and guidance as she helps shape our position in the field of chronic condition management," said Erez Raphael, CEO.
Dr. Hirsch added, "I love Dario's solution and am very excited to be joining their team. Dario's unique digital therapeutics platform is distinguished by its client-centered approach. This facet of the technology has proven successful in engaging users to better manage their health. I look forward to working closely with the Dario team as we further penetrate the B2B market with solutions that advance the management of chronic conditions while positively impacting patients, providers and payers."
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://mydario.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company"
related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company describes its expectation that it will benefit greatly from Dr. Hirsch's unique perspective and guidance as she helps shape its position in the field of chronic condition management and that Dr. Hirsch will work closely with the Dario team as it further penetrates the B2B market with solutions that advance the management of chronic conditions while positively impacting patients, providers and payers, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1 347-767-4220
https://c212.net/c/img/favicon.png?sn=LN11562...2019-10-22 View original content to download multimedia:http://www.prnewswire.com/news-releases/dariohealth-appoints-digital-therapeutics-pioneer-dr-abigail-hirsch-to-its-advisory-board-to-support-commercial-strategy-and-execution-300942898.html
SOURCE DarioHealth Corp.
